bioMérieux, a leader in the field of in vitro diagnostics and FIND (the Foundation for Innovative New Diagnostics), a Swiss non-profit foundation, have signed a Memorandum of Understanding to jointly undertake development projects in the field of infectious disease diagnostics.
Canada
MNA Rizqy and Minister Fitzgibbon honor the employees of bioMérieux Canada Inc. with the National Assembly Medal for their exceptional contribution during the COVID-19 pandemic
27 June, 2022The bioMérieux Canada team remained true to its commitment towards public health by ensuring the installation of the BIOFIRE® systems in record time. The team traveled across Canada despite the sanitary restrictions to ensure adequate user training and was able to demonstrate agility and innovation...
University of Sunderland and bioMérieux Collaborate in New Research Significantly Improving the Identification of Pseudomonas aeruginosa. A Major Cause of Death in Cystic Fibrosis Patients
03 April, 2008
A team of researchers from the University of Sunderland and bioMérieux, a leading company in the field of in vitro diagnostics, have achieved a new step in the fight against Pseudomonas aeruginosa, a bacterium responsible for deadly healthcare-associated infections, which kills tens of thousands of people throughout the world every year .1
FDA Clears bioMérieux’s VIDAS® NT-proBNPA High Medical Value Test for Diagnosis of Heart Failure
13 March, 2008
bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, has received 510(k) clearance from the U.S. Food and Drug Administration to market VIDAS® NT-proBNP, a test that helps the diagnosis of heart failure.
bioMérieux’s Food Safety Handbook is Now Available
26 February, 2008
bioMérieux participates in a project on Legionella and legionellosis
20 February, 2008
bioMérieux and Wescor Bring a New Gram Staining Instrument for Enhanced Microbiology Laboratory Workflow
14 February, 2008
bioMérieux (Euronext: BIM) and Wescor, an ELITech Group Company have signed an agreement by which bioMérieux will become Wescor’s exclusive worldwide partner for marketing two customized slide stainer instruments for Gram and tuberculosis bacillus under the bioMérieux brand.
Quidel and bioMérieux Announce a Global Strategic Alliance in Rapid Diagnostics
15 January, 2008
Quidel Corporation (NASDAQ: QDEL) and bioMérieux (Euronext: BIM) have agreed to form a long-term global alliance in the area of rapid clinical diagnostics for the point-of-care. bioMérieux will become Quidel’s primary distributor for its QuickVue® rapid diagnostic tests outside the United States and the two companies intend to co-develop new rapid tests using Quidel’s market leading rapid test development capability and bioMérieux’s expertise and extensive library of antibodies and antigens. The companies will especially leverage their mutual expertise in the area of infectious diseases.